

CORRIGENDUM

Corrigendum to ‘Impact of asundexian on a panel of coagulation assays’ [Research and Practice in Thrombosis and Haemostasis 9(5) (2025) 102950]

The authors regret that the assay assessing the activity of protein C in plasma was a chromogenic assay, not a chronometric one, as previously indicated.

The corrected text is as follows:

The term “chronometric” should be replaced by “chromogenic” when referring to the protein C assay (p1, methods section of the abstract; p13, discussion section; p13, conclusion, Tables 2 and 3 on p4 and 7).

The commercial name of the kit used to perform this assay should be corrected in Tables 2 and 3 (p4 and 7), as well as in supplementary Table 1 and supplementary Figure 4 (p3 and 10 of the supplementary material file): “HemosIL® ProClot” should be replaced by “HemosIL® Protein C”.

The corresponding reference change value (RCV) should be adjusted (supplementary Table 1, p3 of the supplementary material file): the RCV of the chromogenic assay is 9.2, compared to 19.4 for the chronometric one. This modification does not alter the interpretation of the corresponding results.

The authors would like to apologise for any inconvenience caused.

Jean-Michel Dogné¹

Jonathan Douxfils^{1,2,5}

¹Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, Namur, Belgium

²QUALIresearch, QUALIblood s.a., Liège, Belgium

³Department of Interventional Cardiology, Clinique Saint-Luc Bouge, Bouge, Belgium

⁴Department of Interventional Cardiology, Namur Thrombosis and Hemostasis Center, Centre Hospitalier Universitaire Université Catholique de Louvain (CHU UCL) Namur, Namur, Belgium

⁵Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France

⁶Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Louvain-la-Neuve, Belgium

⁷Hematology Laboratory, Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Centre Hospitalier Universitaire Université Catholique de Louvain (CHU UCL) Namur, Yvoir, Belgium

⁸Department of Clinical Biology, Clinique Saint-Luc Bouge, Bouge, Belgium

⁹Department of Anesthesiology, Centre Hospitalier Universitaire Université Catholique de Louvain (CHU UCL) Namur, Yvoir, Belgium

Julie Vassart¹
Diane Bangoup Ndzatou¹
Marie Didembourg^{1,2}
Laure Morimont^{1,2}
Clotilde Brisbois²
Laurent Jamart³
Fabian Demeure⁴
Aurélien Lebreton⁵
François Mullier^{6,7}
Julien Favresse^{1,8}
Michaël Hardy^{6,7,9}

Correspondence

Jonathan Douxfils, Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences, Faculty of Medicine, University of Namur, 61 rue de Bruxelles, 5000 Namur, Belgium.
Email: jonathan.douxfils@unamur.be